Stay updated on Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial
Sign up to get notified when there's something new on the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page.

Latest updates to the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new revision entry 'Revision: v3.4.2' was added to the history, and a government funding/operating-status notice was removed.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a site-wide notice about funding and operating status, and updated the revision to v3.4.1, replacing the previous revision note v3.4.0.SummaryDifference0.5%

- Check28 days agoChange DetectedThe history page now includes a glossary option and color-coded indicators for additions and deletions, plus a revision banner (v3.4.0). The text 'No FEAR Act Data' appears with capitalization changes and the revision reference updated from v3.3.4 to v3.4.0.SummaryDifference0.7%

- Check35 days agoChange DetectedRevision v3.3.4 was added and revision v3.3.3 was removed from the record, indicating administrative updates to the study history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page history now shows a new release note: Revision: v3.3.3 was added, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page history now includes a new Revision: v3.3.2 entry and appears to remove the previous Revision: v3.3.1 entry. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page.